PrestigeConsumer HEALTHCARE

Prestige Brands Holdings, Inc. Reports Second Quarter & Six Months Fiscal 2007 Results

November 1, 2006

Q2: Revenues Up 15%; Net Income of \$0.18 per Share Up 19%; Free Cash Flow Up 45%

IRVINGTON, N.Y.--(BUSINESS WIRE)--Nov. 1, 2006--Prestige Brands Holdings, Inc. (NYSE:PBH), a consumer products company with a diversified portfolio of well-recognized brands, today announced results for the second quarter and first half of fiscal year 2007, which ended on September 30, 2006. Highlights of the quarter include:

- Total revenues for the second quarter were \$84.6 million, an increase of 15% over the prior year comparable period.
- Excluding the impact of acquisitions, revenues were 7% higher than the prior year comparable period.
- Net income of \$8.8 million, or \$0.18 per share, was 19% higher than the prior year comparable period.
- Free cash flow of \$21.2 million was 45% higher than the prior year comparable period.

Total revenues for the second fiscal quarter ended September 30, 2006 were \$84.6 million, 15% higher than net revenues of \$73.3 million for the prior year comparable period. The increase is due primarily to strong sales in the over-the-counter products (OTC) and household products segments of the business. Revenues resulting from the acquisitions of Chore Boy(R) and The Doctor's(R) brands in the third quarter of fiscal 2006 also contributed to the growth. Excluding the impact of these acquisitions, revenues increased by 7%.

Operating income of \$24.2 million was \$3.4 million, or 16% higher than prior year comparable period operating income of \$20.8 million. The increase in operating profit is primarily due to sales gains in the over-the-counter and household products segments, and a reduction in advertising and promotion spending behind the personal care segment, partially offset by higher general and administrative expenses.

Net income of \$8.8 million, or \$0.18 per fully diluted share for the second quarter of fiscal 2007 was 19% higher than the prior year comparable period net income of \$7.4 million or \$0.15 per fully diluted share.

First Six Months of Fiscal 2007

Total revenues for the first six months of fiscal 2007 were \$160.5 million, an increase of 17% over the comparable prior year period. Excluding the impact of the Chore Boy(R) and The Doctor's(R) brand acquisitions, revenues increased 8%. Operating income of \$47.5 million was 22% higher than prior year comparable period operating income of \$39.1 million. Net income of \$17.0 million, or \$0.34 per fully diluted share, was 28% higher than net income of \$13.3 million or \$0.27 per fully diluted share in the prior year.

Q2 Results by Segment OTC Products: Up 13%

Total revenues of \$46.3 million for the over-the-counter products segment were 13% higher than prior year comparable period revenues of \$40.8 million. Increases in this segment resulted primarily from sales gains in key brands, as well as the acquisition of The Doctor's(R) oral care line acquired in November 2005. Chloraseptic(R), Clear eyes(R), Compound W(R), Little Remedies(R), and Murine(R) all posted increases over the second quarter of fiscal 2006. Excluding the impact of The Doctor's acquisition, revenues increased by 5%.

Household Products: Up 24%

Total revenues for the household products segment were \$31.3 million in the second fiscal quarter, \$6.0 million or 24% higher than the prior year comparable period revenues of \$25.3 million. The two core brands in this business segment, Comet(R) and Spic and Span(R), contributed significantly to this increase, continuing the trend reported in the first fiscal quarter of this year. Excluding the impact of the acquisition of Chore Boy(R), revenues increased by 13%.

Personal Care: Down 4%

Total revenues for the personal care segment were \$7.0 million, a decrease of 4% compared to prior year period revenues of \$7.3 million. This decline reflects continued softness in two of the three key brands in this segment.

First Six Months by Segment OTC Products: Up 16%

Total revenues of \$85.9 million for the over-the-counter products segment were 16% greater than prior year comparable period revenues of \$74.1 million. The increase resulted primarily from sales increases for the major brands in the segment; Chloraseptic(R), Clear eyes(R), Compound W(R), Little Remedies(R), Murine(R), Dermoplast(R), as well as sales of The Doctor's(R) oral care line acquired in November 2005. Excluding the impact of The Doctor's acquisition, revenues increased by 7%.

Household Products: Up 28%

Total revenues of \$61.3 million for the household products segment were \$13.3 million, or 28% greater than the prior year comparable period. The increase was due to strong year over year gains for the Comet(R) and Spic and Span(R) brands, as well as the Chore Boy(R) acquisition in October of 2005. Excluding the impact of the Chore Boy acquisition, revenues increased by 13%.

Personal Care: Down 9%

Total revenues of \$13.3 million for the personal care segment were \$5.3 million, or 9% below revenues of \$14.6 million for the comparable prior year

period, primarily due to declines in the Cutex(R) and Denorex(R) brands.

Free Cash Flow

Free cash flow is a "non-GAAP" financial measure" as that term is defined by the Securities and Exchange Commission in Regulation G. Free cash flow is presented in this news release because management believes that it is a commonly used measure of liquidity, and is indicative of cash available for debt repayment and acquisitions. The Company defines "free cash flow" as operating cash flow less capital expenditures.

The Company's free cash flow for the quarter ended September 30, 2006 was \$21.2 million, composed of operating cash flows of \$21.2 million, less capital expenditures of \$0.0 million. Free cash flow for the six months ended September 30, 2006 was \$42.4 million, composed of operating cash flows of \$42.7 million, less capital expenditures of \$0.3 million. The Company's free cash flow was higher than net income primarily due to the amortization of intangible assets, cash provided by a working capital decline, and relatively low capital expenditures.

Acquisition Announced

On September 25, 2006, the Company announced the acquisition of Wartner USA B.V., the owner of the Wartner(R) brand of over-the-counter wart treatment products for approximately \$31.2 million in cash and the assumption of approximately \$5 million of contingent payments to a former owner. Wartner is the #3 brand in the U.S. over-the-counter wart treatment category with approximately \$11 million in trailing 12 month sales. The Company also markets the Compound W(R) line of wart treatment products and believes this strategic acquisition will enhance its leadership in the category. This acquisition had no material effect on the operating results of the second fiscal quarter.

Commentary and Outlook

Commenting on the results of the quarter and the first half of fiscal 2007, Peter C. Mann, Chairman and CEO said, "We are pleased with the results of the fiscal year to date which are in line with our expectations. The Company's financial position is strong, our key brand franchises are healthy, and we have a good pipeline of new items and programs. For the full fiscal year 2007, we expect that organic revenue growth, excluding the impact of acquisitions, will be slightly above our long-term growth outlook of 3-4%, and net income will grow less rapidly than total revenue growth. In the second half of the year, net income will be somewhat impacted by higher investments in A&P support behind many of our key brands."

Conference Call

The Company will host a conference call to review its second quarter and six month results on Thursday, November 2nd at 8:30am EST. The toll free number is 866-202-3109 within North America and 617-213-8844 from outside North America. The conference pass code is "prestige". Telephonic replays will be available for two weeks following completion of the call and can be accessed at 888-286-8010 within North America and at 617-801-6888 from outside North America. The pass code is 54554715.

About Prestige Brands Holdings, Inc.

Located in Irvington, New York, Prestige Brands Holdings, Inc. is a marketer and distributor of brand name over-the-counter, personal care and household products sold throughout the U.S. and Canada. Key brands include Compound W(R) wart remover, Chloraseptic(R) sore throat treatment, New-Skin(R) liquid bandage, Clear eyes(R) and Murine(R) eye care products, Little Remedies(R) pediatric over-the-counter products, Cutex(R) nail polish remover, Comet(R) and Spic and Span(R) household products, and other well-known brands.

Forward Looking Statements

Note: This news release may contain "forward-looking statements" within the meaning of the federal securities laws and is intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" generally can be identified by the use of forward-looking terminology such as "assumptions," "target," "guidance," "outlook," "plans," "projection," "may," "will," "would," "expect," "intend," "estimate," "anticipate," "believe, "potential," or "continue" (or the negative or other derivatives of each of these terms) or similar terminology. The "forward-looking statements" include, without limitation, statements regarding the outlook for Prestige Brands Holdings' market and the demand for its products, earnings per share, future cash flows from operations, future revenues and margin requirement and expansion, the success of new product introductions, growth in costs and expenses, and the impact of acquisitions, divestitures, restructurings and other unusual items, including Prestige Brands Holdings' ability to integrate and obtain the anticipated results and synergies from its acquisitions. These projections and statements are based on management's estimates and assumptions with respect to future events and financial performance and are believed to be reasonable, though are inherently uncertain and difficult to predict. Actual results could differ materially from those projected as a result of certain factors. A discussion of factors that could cause results to vary is included in the Company's Annual Report on Form 10-K and other periodic and other reports filed with the Securities and Exchange Commission.

Prestige Brands Holdings, Inc. Consolidated Statements of Operations (Unaudited)

	Three M Ended Sept		Six Mo: Ended Sept	
(In thousands, except per sha data)	re 2006	2005	2006	2005
Revenues Net sales Other revenues	\$84,033 518	\$73,320 25	\$159,600 874	\$136,748 50
Total revenues	84,551	73,345	160,474	136,798

Cost of Sales				
Costs of sales			77,584	
Gross profit			82,890	
Operating Expenses Advertising and promotion	9,455	10,217	16,857	18,922
	7,259			
Depreciation	219	487	439	975
Amortization of intangible				
assets	-	-	4,386	-
Total operating expenses	19,126	16,969	35,375	33,216
Operating income	24,166	20,827		
Other income (expense)	400	000	500	205
Interest income Interest expense			588 (20,123)	
Interest expense			(20,123)	
Total other income				
(expense)	(9,743)	(8,671)	(19,535)	(17,181)
Income before provision		10 1EC	27,980	21 002
income taxes	14,423	12,150	27,980	21,903
rovision for income taxes	5,639	4,782		8,600
Net income	\$8,784		\$17,040	\$13,303
	========			
ania anninan ann abana	¢0.10	ĊO 15	άο ος	¢0 07
asic earnings per share	\$0.18 =======		\$0.35 ======	
Diluted earnings per share	\$0.18	\$0.15	\$0.34	\$0.27
riacca carnings per share			=======	
Weighted average shares				
outstanding:				
Basic		-	49,389 ======	-
Diluted			49,991	
	========			
_	Brands Holdi egment Result	-		
5	(Unaudited)	-5		
	Three Mont		eptember 3	
	Over-the- Ho Counter Cl	usehold Pe	rsonal	
	Drug	canting		
(in thousands)				
Net sales	\$46,255 \$	30,732 \$	7,046	\$84,033
Other revenues		518		518

----- ------ ------

Total revenues	46 255	31 250	7 046	84 551
Cost of sales				84,551 41,259
Gross profit				43,292
Advertising and promotion				9,455
Contribution margin				
Other operating expenses		=======		9,671
Operating income				24,166
Other (income) expense				9,743
Provision for income taxes			-	5,639
Net income				\$8,784
	Six Mo:	nths Ended		r 30, 2006
				Consolidated
	Drug			
(in thousands)				
Net sales	\$85,853	\$60,470	\$13,277	\$159,600
Other revenues		874		874
Total revenues	85 853	61 344	13 277	160,474
Cost of sales				77,584
Gross profit	53,455	24,249	5,186	82,890
Advertising and promotion	12,483	3,710	664	16,857
Contribution margin		\$20,539		
Other operating expenses				18,518
Operating income				47,515
Other (income) expense				19,535
Provision for income taxes				10,940
Net income				\$17,040
			:	=======
	Three M	onths Ende	d Septemb	er 30, 2005
		Household		
	Counter Drug	Cleaning	Care	Consolidated
(in thousands)				
Net sales	\$40,759	\$25,229	\$7,332	\$73,320
Other revenues		25		25

-- 25 -- 25

Other revenues

Total revenues Cost of sales	40,759 15,558	25,254 15,535	7,332 4,456	73,345 35,549
Gross profit Advertising and promotion				37,796 10,217
Contribution margin				
Other operating expenses				6,752
Operating income Other income (expense) Provision for income taxes			-	20,827 (8,671) (4,782)
Net income			=	\$7,374
		nths Ended	-	
	Over-the-	Household	Personal	
(in thousands) Net sales Other revenues	\$74,148	\$48,012 50		\$136,748 50
Total revenues Cost of sales	27,223	28,922	8,353	136,798 64,498
Gross profit Advertising and promotion	13,266	19,140 3,510	2,146	72,300 18,922
Contribution margin		\$15,630		53,378
Other operating expenses				14,294
Operating income Other income (expense) Provision for income taxes			-	39,084 (17,181) (8,600)
Net income			=	\$13,303
		oldings, In ance Sheet ed)		
(In thousands)	2	September 3	0, 2006 №	March 31, 2000
Assets Current assets		A1	0 509	čo 200

Cash	\$10,508	\$8,200
Accounts receivable	37,447	40,042

Inventories	29,272	33,841			
Deferred income tax assets Prepaid expenses and other current	2,405	3,227			
assets	1,748	701			
Total current assets	81,380	86,011			
Property and equipment	1,527	1,653			
Goodwill	302,786	297,935			
Intangible assets Other long-term assets	662,290 13,815	637,197			
	13,615	15,849			
Total Assets	\$1,061,798	\$1,038,645			
Liabilities and Stockholders' Equity Current liabilities					
Accounts payable	\$22.584	\$18,065			
Accrued interest payable	7,773	7,563			
Income taxes payable	64	1,795			
Other accrued liabilities	8,714	4,582			
Current portion of long-term debt	3,730	3,730			
Total current liabilities	42,865	35,735			
Long-term debt	486,035	494,900			
Other accrued liabilities	2,801				
Deferred income tax liabilities	103,954	98,603			
-					
Total liabilities	635,655	629,238			
<pre>Stockholders' Equity Preferred stock - \$0.01 par value Authorized - 5,000 shares Issued and outstanding - None Common stock - \$0.01 par value Authorized - 250,000 shares Issued and outstanding - 50,060 shares at September 30, 2006 and</pre>					
March 31, 2006	501	501			
Additional paid-in capital Treasury stock, at cost - 52 shares at September 30, 2006 and 18 shares	378,794	378,570			
at March 31, 2006 Accumulated other comprehensive	(36)	(30)			
income	587	1,109			
Retained earnings	46,297	-			
Total stockholders' equity	426,143	409,407			
Total Liabilities and Stockholders' Equity	\$1,061,798	\$1,038,645			
Prestige Brands Holdings, Inc. Consolidated Statements of Cash Flows (Unaudited)					

Six Months Ended September 30

	2006	2005
Operating Activities		
Net income	\$17,040	\$13,303
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	4,825	5,271
Deferred income taxes Amortization of deferred financing	6,197	7,961
costs	1,609	1,136
Stock-based compensation	224	110
Changes in operating assets and liabilities		
Accounts receivable	2,595	3,366
Inventories	5,202	(8,054)
Prepaid expenses and other current	·	. ,
assets	(1,047)	(104)
Accounts payable		1,020
Income taxes payable	(1,731)	
Accrued liabilities		521
Net cash provided by operating		
activities	42,734	24,530
Investing Activities Purchases of equipment Purchase of business Net cash used for investing activities	(31,242)	
Net cash used for investing activities	(31,333)	
Financing Activities Repayment of notes	(8,865)	(1,865)
Payment of deferred financing costs		(33)
Purchase of common stock for treasury Additional costs associated with initia	. ,	(21)
public offering		(63)
Net cash used for financing activities	(8,871)	(1,982
Increase in cash	2,308	22,251
Cash - beginning of period	8,200	5,334
cash segunning of period		
Cash - end of period	¢10 E00	007 E0F
Cash - end of period	\$10,508	
	=======================================	